var mockData = {
  mockData      : {"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$gsx":"http://schemas.google.com/spreadsheets/2006/extended","id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"FIN-RACo"},"link":[{"rel":"alternate","type":"application/atom+xml","href":"https://docs.google.com/spreadsheets/d/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/pubhtml"},{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values"},{"rel":"http://schemas.google.com/g/2005#post","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values"},{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values?alt=json"}],"author":[{"name":{"$t":"adamibaker"},"email":{"$t":"adamibaker@gmail.com"}}],"openSearch$totalResults":{"$t":"41"},"openSearch$startIndex":{"$t":"1"},"entry":[{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cokwr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"key"},"content":{"type":"text","$t":"measure: i.e. outcome, metric: i.e. statistic, valuecilow: 95% ci low, valuecihigh: 95% ci high, valuesd: standard deviation, valueiqrlow: interquartile range, valueiqrhigh: interquartile range, grade: GRADE quality, ntotal: number of participants, durationlow: low end of duration or follow-up, durationhigh: high end of duration or follow-up, population: population / characteristic, intervention: intervention(s)\ncomma-separated, comparison: comparison(s),\ncomma-separated, dosageform: comma-separated, dosageinterval: once | prn | hour | day | week | month | year, notes: notes"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cokwr"}],"gsx$which":{"$t":"key"},"gsx$measure":{"$t":"i.e. outcome"},"gsx$metric":{"$t":"i.e. statistic"},"gsx$value":{"$t":""},"gsx$valuecilow":{"$t":"95% ci low"},"gsx$valuecihigh":{"$t":"95% ci high"},"gsx$valuesd":{"$t":"standard deviation"},"gsx$valueiqrlow":{"$t":"interquartile range"},"gsx$valueiqrhigh":{"$t":"interquartile range"},"gsx$grade":{"$t":"GRADE quality"},"gsx$ntotal":{"$t":"number of participants"},"gsx$durationlow":{"$t":"low end of duration or follow-up"},"gsx$durationhigh":{"$t":"high end of duration or follow-up"},"gsx$durationinterval":{"$t":""},"gsx$population":{"$t":"population / characteristic"},"gsx$intervention":{"$t":"intervention(s)\ncomma-separated"},"gsx$comparison":{"$t":"comparison(s),\ncomma-separated"},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":"comma-separated"},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":"once | prn | hour | day | week | month | year"},"gsx$source":{"$t":""},"gsx$notes":{"$t":"notes"},"gsx$kind":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cpzh4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: remission, metric: percentage, value: 0.26, ntotal: 78, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, intervention: methotrexate,sulfasalazine,hydroxychloroquine,prednisolone, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cpzh4"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"remission"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.26"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"78"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":"methotrexate,sulfasalazine,hydroxychloroquine,prednisolone"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cre1l"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: remission, metric: percentage, value: 0.11, ntotal: 81, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, intervention: sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cre1l"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"remission"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.11"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"81"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":"sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/chk2m"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: acr_50, metric: percentage, value: 0.42, ntotal: 78, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, intervention: methotrexate,sulfasalazine,hydroxychloroquine,prednisolone, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/chk2m"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"acr_50"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.42"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"78"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":"methotrexate,sulfasalazine,hydroxychloroquine,prednisolone"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ciyn3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: acr_50, metric: percentage, value: 0.41, ntotal: 81, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, intervention: sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ciyn3"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"acr_50"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.41"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"81"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":"sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ckd7g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: arc_20, metric: percentage, value: 0.12, ntotal: 78, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, intervention: methotrexate,sulfasalazine,hydroxychloroquine,prednisolone, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ckd7g"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"arc_20"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.12"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"78"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":"methotrexate,sulfasalazine,hydroxychloroquine,prednisolone"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/clrrx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: acr_20, metric: percentage, value: 0.25, ntotal: 81, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, intervention: sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/clrrx"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"acr_20"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.25"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"81"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":"sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cyevm"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: sub_acr_20, metric: percentage, value: 0.21, ntotal: 78, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, intervention: methotrexate,sulfasalazine,hydroxychloroquine,prednisolone, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cyevm"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"sub_acr_20"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.21"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"78"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":"methotrexate,sulfasalazine,hydroxychloroquine,prednisolone"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cztg3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"intervention"},"content":{"type":"text","$t":"measure: sub_acr_20, metric: percentage, value: 0.23, ntotal: 81, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, intervention: sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cztg3"}],"gsx$which":{"$t":"intervention"},"gsx$measure":{"$t":"sub_acr_20"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.23"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"81"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":"sulfasalazine,prednisolone (optional),switch to methotrexate if inadequate response on sulfasalazine"},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":""},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d180g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: patient_global_das, metric: mean_score_100, value: 4, valuesd: 5, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d180g"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"patient_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"4"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"5"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d2mkx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: patient_global_das, metric: mean_score_100, value: 16, valuesd: 14, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d2mkx"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"patient_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"16"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"14"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cssly"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: patient_global_das, metric: mean_score_100, value: 31, valuesd: 19, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cssly"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"patient_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"31"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"19"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cu76f"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: patient_global_das, metric: mean_score_100, value: 47, valuesd: 43, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cu76f"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"patient_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"47"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"43"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cvlqs"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: physician_global_das, metric: mean_score_100, value: 1, valuesd: 4, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cvlqs"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"physician_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"1"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"4"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cx0b9"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: physician_global_das, metric: mean_score_100, value: 11, valuesd: 8, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/cx0b9"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"physician_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"11"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"8"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d9ney"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: physician_global_das, metric: mean_score_100, value: 28, valuesd: 14, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d9ney"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"physician_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"28"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"14"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/db1zf"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: physician_global_das, metric: mean_score_100, value: 38, valuesd: 19, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/db1zf"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"physician_global_das"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"38"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"19"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dcgjs"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: pain, metric: mean_score_100, value: 3, valuesd: 5, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dcgjs"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"pain"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"3"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"5"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ddv49"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: pain, metric: mean_score_100, value: 15, valuesd: 15, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/ddv49"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"pain"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"15"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"15"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d415a"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: pain, metric: mean_score_100, value: 27, valuesd: 17, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d415a"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"pain"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"27"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"17"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d5fpr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: pain, metric: mean_score_100, value: 40, valuesd: 23, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d5fpr"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"pain"},"gsx$metric":{"$t":"mean_score_100"},"gsx$value":{"$t":"40"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"23"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d6ua4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: haq, metric: mean_score, value: 0.0, valuesd: 0.2, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d6ua4"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"haq"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0.0"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"0.2"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d88ul"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: haq, metric: mean_score, value: 0.2, valuesd: 0.3, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/d88ul"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"haq"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0.2"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"0.3"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dkvya"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: haq, metric: mean_score, value: 0.4, valuesd: 0.4, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dkvya"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"haq"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0.4"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"0.4"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dmair"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: haq, metric: mean_score, value: 0.6, valuesd: 0.5, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dmair"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"haq"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0.6"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"0.5"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dnp34"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: tjc, metric: mean_score, value: 0, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dnp34"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"tjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dp3nl"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: tjc, metric: mean_score, value: 4, valuesd: 2, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dp3nl"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"tjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"4"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"2"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/df9om"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: tjc, metric: mean_score, value: 10, valuesd: 5, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/df9om"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"tjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"10"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"5"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dgo93"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: tjc, metric: mean_score, value: 15, valuesd: 7, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dgo93"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"tjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"15"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"7"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/di2tg"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: sjc, metric: mean_score, value: 0, ntotal: 29, durationlow: 6, durationinterval: month, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/di2tg"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"sjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"0"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/djhdx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: sjc, metric: mean_score, value: 2, valuesd: 2, ntotal: 66, durationlow: 6, durationinterval: month, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/djhdx"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"sjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"2"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"2"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dw4je"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: sjc, metric: mean_score, value: 5, valuesd: 5, ntotal: 29, durationlow: 6, durationinterval: month, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dw4je"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"sjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"5"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"5"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dxj3v"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: sjc, metric: mean_score, value: 8, valuesd: 7, ntotal: 35, durationlow: 6, durationinterval: month, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dxj3v"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"sjc"},"gsx$metric":{"$t":"mean_score"},"gsx$value":{"$t":"8"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":"7"},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"6"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"month"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dyxo8"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: permanent_work_disability, metric: percentage, value: 0, ntotal: 29, durationlow: 5, durationinterval: year, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dyxo8"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"permanent_work_disability"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e0c8p"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: permanent_work_disability, metric: percentage, value: 0.23, ntotal: 66, durationlow: 5, durationinterval: year, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e0c8p"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"permanent_work_disability"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.23"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dqi9q"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: permanent_work_disability, metric: percentage, value: 0.21, ntotal: 29, durationlow: 5, durationinterval: year, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dqi9q"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"permanent_work_disability"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.21"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/drwu7"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: permanent_work_disability, metric: percentage, value: 0.54, ntotal: 35, durationlow: 5, durationinterval: year, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/drwu7"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"permanent_work_disability"},"gsx$metric":{"$t":"percentage"},"gsx$value":{"$t":"0.54"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":""},"gsx$valueiqrhigh":{"$t":""},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dtbek"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: median_work_disability_days, metric: count, value: 0, valueiqrlow: 0, valueiqrhigh: 3, ntotal: 29, durationlow: 5, durationinterval: year, population: Remission after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dtbek"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"median_work_disability_days"},"gsx$metric":{"$t":"count"},"gsx$value":{"$t":"0"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":"0"},"gsx$valueiqrhigh":{"$t":"3"},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"Remission after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dupz1"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: median_work_disability_days, metric: count, value: 4, valueiqrlow: 0, valueiqrhigh: 131, ntotal: 66, durationlow: 5, durationinterval: year, population: ACR 50 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/dupz1"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"median_work_disability_days"},"gsx$metric":{"$t":"count"},"gsx$value":{"$t":"4"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":"0"},"gsx$valueiqrhigh":{"$t":"131"},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"66"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"ACR 50 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e7d2q"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: median_work_disability_days, metric: count, value: 15, valueiqrlow: 0, valueiqrhigh: 170, ntotal: 29, durationlow: 5, durationinterval: year, population: ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e7d2q"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"median_work_disability_days"},"gsx$metric":{"$t":"count"},"gsx$value":{"$t":"15"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":"0"},"gsx$valueiqrhigh":{"$t":"170"},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"29"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e8rn7"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"population"},"content":{"type":"text","$t":"measure: median_work_disability_days, metric: count, value: 337, valueiqrlow: 27, valueiqrhigh: 365, ntotal: 35, durationlow: 5, durationinterval: year, population: Less than ACR 20 after 6 months of treatment, dosage: 6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine, source: http://www.ncbi.nlm.nih.gov/pubmed/15641055, kind: randomized trial"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oclozwl/public/values/e8rn7"}],"gsx$which":{"$t":"population"},"gsx$measure":{"$t":"median_work_disability_days"},"gsx$metric":{"$t":"count"},"gsx$value":{"$t":"337"},"gsx$valuecilow":{"$t":""},"gsx$valuecihigh":{"$t":""},"gsx$valuesd":{"$t":""},"gsx$valueiqrlow":{"$t":"27"},"gsx$valueiqrhigh":{"$t":"365"},"gsx$grade":{"$t":""},"gsx$ntotal":{"$t":"35"},"gsx$durationlow":{"$t":"5"},"gsx$durationhigh":{"$t":""},"gsx$durationinterval":{"$t":"year"},"gsx$population":{"$t":"Less than ACR 20 after 6 months of treatment"},"gsx$intervention":{"$t":""},"gsx$comparison":{"$t":""},"gsx$dosage":{"$t":"6 months of methotrexate + sulfasalazine + hydroxychloroquine + prednisolone OR sulfasalazine + prednisolone (optional) + switch to methotrexate if inadequate response on sulfasalazine"},"gsx$dosageform":{"$t":""},"gsx$dosagefrequency":{"$t":""},"gsx$dosagemultiple":{"$t":""},"gsx$dosageinterval":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/15641055"},"gsx$notes":{"$t":""},"gsx$kind":{"$t":"randomized trial"}}]}},
  mockGrades    : {"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$gsx":"http://schemas.google.com/spreadsheets/2006/extended","id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"GRADE"},"link":[{"rel":"alternate","type":"application/atom+xml","href":"https://docs.google.com/spreadsheets/d/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/pubhtml"},{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values"},{"rel":"http://schemas.google.com/g/2005#post","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values"},{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values?alt=json"}],"author":[{"name":{"$t":"adamibaker"},"email":{"$t":"adamibaker@gmail.com"}}],"openSearch$totalResults":{"$t":"6"},"openSearch$startIndex":{"$t":"1"},"entry":[{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cokwr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"level of evidence"},"content":{"type":"text","$t":"namefriendly: human-friendly name, descriptionfriendly: human-friendly description, notes: notes"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cokwr"}],"gsx$grade":{"$t":"level of evidence"},"gsx$namefriendly":{"$t":"human-friendly name"},"gsx$description":{"$t":""},"gsx$descriptionfriendly":{"$t":"human-friendly description"},"gsx$source":{"$t":""},"gsx$notes":{"$t":"notes"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cpzh4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"4"},"content":{"type":"text","$t":"namefriendly: High quality, description: Further research is very unlikely to change our confidence in the estimate of effect., descriptionfriendly: Doctors and researchers are confident in the results. They don't think that more research would change the results, and think that the studies done so far have been reliable and well-done., source: http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cpzh4"}],"gsx$grade":{"$t":"4"},"gsx$namefriendly":{"$t":"High quality"},"gsx$description":{"$t":"Further research is very unlikely to change our confidence in the estimate of effect."},"gsx$descriptionfriendly":{"$t":"Doctors and researchers are confident in the results. They don't think that more research would change the results, and think that the studies done so far have been reliable and well-done."},"gsx$source":{"$t":"http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cre1l"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"3"},"content":{"type":"text","$t":"namefriendly: Moderate quality, description: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate., descriptionfriendly: Doctors and researchers aren't completely confident in the results. They think that more research might change their minds, and might even produce different results. They think that the studies done so far have been OK, but that there isn't enough data to make them completely confident., source: http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/cre1l"}],"gsx$grade":{"$t":"3"},"gsx$namefriendly":{"$t":"Moderate quality"},"gsx$description":{"$t":"Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate."},"gsx$descriptionfriendly":{"$t":"Doctors and researchers aren't completely confident in the results. They think that more research might change their minds, and might even produce different results. They think that the studies done so far have been OK, but that there isn't enough data to make them completely confident."},"gsx$source":{"$t":"http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/chk2m"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"2"},"content":{"type":"text","$t":"namefriendly: Low quality, description: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate., descriptionfriendly: Doctors and researchers aren't confident in the results. They think that more research would likely change their minds, and probably produce different results. The change could be positive, or negative. They think that the studies done so far weren't well-done enough to make them confident in the results., source: http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/chk2m"}],"gsx$grade":{"$t":"2"},"gsx$namefriendly":{"$t":"Low quality"},"gsx$description":{"$t":"Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate."},"gsx$descriptionfriendly":{"$t":"Doctors and researchers aren't confident in the results. They think that more research would likely change their minds, and probably produce different results. The change could be positive, or negative. They think that the studies done so far weren't well-done enough to make them confident in the results."},"gsx$source":{"$t":"http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/ciyn3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"1"},"content":{"type":"text","$t":"namefriendly: Very low quality, description: We are very uncertain about the estimate., descriptionfriendly: Doctors and researchers don't have confidence in the results. They think the studies done so far have flaws that make the results unreliable, and that more research is needed on this topic., source: http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/ciyn3"}],"gsx$grade":{"$t":"1"},"gsx$namefriendly":{"$t":"Very low quality"},"gsx$description":{"$t":"We are very uncertain about the estimate."},"gsx$descriptionfriendly":{"$t":"Doctors and researchers don't have confidence in the results. They think the studies done so far have flaws that make the results unreliable, and that more research is needed on this topic."},"gsx$source":{"$t":"http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/ckd7g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"X"},"content":{"type":"text","$t":"namefriendly: Unknown quality, description: The evidence has not been quality-rated., descriptionfriendly: Doctors and researchers haven't quality-rated this information according to the GRADE guidelines."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/oo3g5h2/public/values/ckd7g"}],"gsx$grade":{"$t":"X"},"gsx$namefriendly":{"$t":"Unknown quality"},"gsx$description":{"$t":"The evidence has not been quality-rated."},"gsx$descriptionfriendly":{"$t":"Doctors and researchers haven't quality-rated this information according to the GRADE guidelines."},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}}]}},
  mockMeasures  : {"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$gsx":"http://schemas.google.com/spreadsheets/2006/extended","id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"Measures"},"link":[{"rel":"alternate","type":"application/atom+xml","href":"https://docs.google.com/spreadsheets/d/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/pubhtml"},{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values"},{"rel":"http://schemas.google.com/g/2005#post","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values"},{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values?alt=json"}],"author":[{"name":{"$t":"adamibaker"},"email":{"$t":"adamibaker@gmail.com"}}],"openSearch$totalResults":{"$t":"23"},"openSearch$startIndex":{"$t":"1"},"entry":[{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cokwr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"measure name / code"},"content":{"type":"text","$t":"namefriendly: measure name (human-readable), namelong: measure name (longer), tags: comma-separated, kind: examination, assay, questionnaire, scale, instrument NOS,count, max: max value, if applicable, relatedmeasures: comma-separated, includedmeasures: comma-separated, notes: notes"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cokwr"}],"gsx$name":{"$t":"measure name / code"},"gsx$nameshort":{"$t":""},"gsx$namefriendly":{"$t":"measure name (human-readable)"},"gsx$namelong":{"$t":"measure name (longer)"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"comma-separated"},"gsx$kind":{"$t":"examination, assay, questionnaire, scale, instrument NOS,count"},"gsx$variable":{"$t":""},"gsx$max":{"$t":"max value, if applicable"},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":"comma-separated"},"gsx$includedmeasures":{"$t":"comma-separated"},"gsx$source":{"$t":""},"gsx$notes":{"$t":"notes"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cpzh4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"tjc"},"content":{"type":"text","$t":"nameshort: TJC, namefriendly: tender joint count, namelong: ACR tender joint count, description: \"An assessment of 28 or more joints. The joint count should be done by scoring several different aspects of tenderness, as assessed by pressure and joint manipulation on physical examination. The information on various types of tenderness should then be collapsed into a single tender-versus-nontender dichotomy.\", tags: pain,function, kind: examination, variable: interval, assessor: clinician, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cpzh4"}],"gsx$name":{"$t":"tjc"},"gsx$nameshort":{"$t":"TJC"},"gsx$namefriendly":{"$t":"tender joint count"},"gsx$namelong":{"$t":"ACR tender joint count"},"gsx$description":{"$t":"\"An assessment of 28 or more joints. The joint count should be done by scoring several different aspects of tenderness, as assessed by pressure and joint manipulation on physical examination. The information on various types of tenderness should then be collapsed into a single tender-versus-nontender dichotomy.\""},"gsx$tags":{"$t":"pain,function"},"gsx$kind":{"$t":"examination"},"gsx$variable":{"$t":"interval"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cre1l"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"sjc"},"content":{"type":"text","$t":"nameshort: SJC, namefriendly: swollen joint count, namelong: ACR swollen joint count, description: \"An assessment of 28 or more joints. Joints are classified as swollen or not swollen.\", tags: swelling,function, kind: examination, variable: interval, assessor: clinician, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cre1l"}],"gsx$name":{"$t":"sjc"},"gsx$nameshort":{"$t":"SJC"},"gsx$namefriendly":{"$t":"swollen joint count"},"gsx$namelong":{"$t":"ACR swollen joint count"},"gsx$description":{"$t":"\"An assessment of 28 or more joints. Joints are classified as swollen or not swollen.\""},"gsx$tags":{"$t":"swelling,function"},"gsx$kind":{"$t":"examination"},"gsx$variable":{"$t":"interval"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/chk2m"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"acr_tjc"},"content":{"type":"text","$t":"nameshort: TJC, namefriendly: tender joint count, namelong: ACR tender joint count, description: \"An assessment of 28 or more joints. The joint count should be done by scoring several different aspects of tenderness, as assessed by pressure and joint manipulation on physical examination. The information on various types of tenderness should then be collapsed into a single tender-versus-nontender dichotomy.\", tags: pain,function, kind: examination, variable: interval, assessor: clinician, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/chk2m"}],"gsx$name":{"$t":"acr_tjc"},"gsx$nameshort":{"$t":"TJC"},"gsx$namefriendly":{"$t":"tender joint count"},"gsx$namelong":{"$t":"ACR tender joint count"},"gsx$description":{"$t":"\"An assessment of 28 or more joints. The joint count should be done by scoring several different aspects of tenderness, as assessed by pressure and joint manipulation on physical examination. The information on various types of tenderness should then be collapsed into a single tender-versus-nontender dichotomy.\""},"gsx$tags":{"$t":"pain,function"},"gsx$kind":{"$t":"examination"},"gsx$variable":{"$t":"interval"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ciyn3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"acr_sjc"},"content":{"type":"text","$t":"nameshort: SJC, namefriendly: swollen joint count, namelong: ACR swollen joint count, description: \"An assessment of 28 or more joints. Joints are classified as swollen or not swollen.\", tags: swelling,function, kind: examination, variable: interval, assessor: clinician, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ciyn3"}],"gsx$name":{"$t":"acr_sjc"},"gsx$nameshort":{"$t":"SJC"},"gsx$namefriendly":{"$t":"swollen joint count"},"gsx$namelong":{"$t":"ACR swollen joint count"},"gsx$description":{"$t":"\"An assessment of 28 or more joints. Joints are classified as swollen or not swollen.\""},"gsx$tags":{"$t":"swelling,function"},"gsx$kind":{"$t":"examination"},"gsx$variable":{"$t":"interval"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ckd7g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"patient_pain"},"content":{"type":"text","$t":"nameshort: pain, namefriendly: patient's assessment of pain, namelong: Patient's assessment of pain, description: \"A horizontal visual analog scale (usually 10 cm) or Likert scale assessment of the patient's current level of pain.\", tags: pain, kind: scale, variable: continuous, assessor: patient, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ckd7g"}],"gsx$name":{"$t":"patient_pain"},"gsx$nameshort":{"$t":"pain"},"gsx$namefriendly":{"$t":"patient's assessment of pain"},"gsx$namelong":{"$t":"Patient's assessment of pain"},"gsx$description":{"$t":"\"A horizontal visual analog scale (usually 10 cm) or Likert scale assessment of the patient's current level of pain.\""},"gsx$tags":{"$t":"pain"},"gsx$kind":{"$t":"scale"},"gsx$variable":{"$t":"continuous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/clrrx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"patient_global_das"},"content":{"type":"text","$t":"nameshort: patient global assessment, namefriendly: patient's global assessment of disease activity, namelong: Patient's global assessment of disease activity, description: \"The patient's overall assessment of how the arthritis is doing. One acceptable method for determining this is the question from the AIMS instrument: \"Considering all the ways your arthritis affects you, mark 'X' on the scale for how well you are doing.\" An anchored, horizontal, visual analog scale (usually 10 cm) should be provided. A Likert scale response is also acceptable.\", tags: well being, kind: scale, variable: continuous, assessor: patient, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/clrrx"}],"gsx$name":{"$t":"patient_global_das"},"gsx$nameshort":{"$t":"patient global assessment"},"gsx$namefriendly":{"$t":"patient's global assessment of disease activity"},"gsx$namelong":{"$t":"Patient's global assessment of disease activity"},"gsx$description":{"$t":"\"The patient's overall assessment of how the arthritis is doing. One acceptable method for determining this is the question from the AIMS instrument: \"Considering all the ways your arthritis affects you, mark 'X' on the scale for how well you are doing.\" An anchored, horizontal, visual analog scale (usually 10 cm) should be provided. A Likert scale response is also acceptable.\""},"gsx$tags":{"$t":"well being"},"gsx$kind":{"$t":"scale"},"gsx$variable":{"$t":"continuous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cyevm"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"physician_global_das"},"content":{"type":"text","$t":"nameshort: physician global assessment, namefriendly: physician's global assessent of disease activity, namelong: Physician's global assessent of disease activity, description: \"A horizontal visual analog scale (usually 10 cm) or Likert scale measure of the physician's assessment of the patient's current disease activity.\", tags: well being, kind: scale, variable: continuous, assessor: clinician, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cyevm"}],"gsx$name":{"$t":"physician_global_das"},"gsx$nameshort":{"$t":"physician global assessment"},"gsx$namefriendly":{"$t":"physician's global assessent of disease activity"},"gsx$namelong":{"$t":"Physician's global assessent of disease activity"},"gsx$description":{"$t":"\"A horizontal visual analog scale (usually 10 cm) or Likert scale measure of the physician's assessment of the patient's current disease activity.\""},"gsx$tags":{"$t":"well being"},"gsx$kind":{"$t":"scale"},"gsx$variable":{"$t":"continuous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cztg3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"patient_physical_function"},"content":{"type":"text","$t":"nameshort: physical function, namefriendly: patient's assessment of physical function, namelong: Patient's assessment of physical function, description: \"Any patient self-assessment instrument which has been validated, has reliability, has been proven in RA trials to be sensitive to change, and which measures physical function in RA patients is acceptable. Instruments which have been demonstrated to be sensitive in RA trials include the AIMS, the HAQ, the Quality (or Index) of Well Being, the MHIQ, and the MACTAR., tags: function, kind: composite, assessor: patient, includedmeasures: aims,haq,qwb,iwb,mhiq,mactar, source: http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cztg3"}],"gsx$name":{"$t":"patient_physical_function"},"gsx$nameshort":{"$t":"physical function"},"gsx$namefriendly":{"$t":"patient's assessment of physical function"},"gsx$namelong":{"$t":"Patient's assessment of physical function"},"gsx$description":{"$t":"\"Any patient self-assessment instrument which has been validated, has reliability, has been proven in RA trials to be sensitive to change, and which measures physical function in RA patients is acceptable. Instruments which have been demonstrated to be sensitive in RA trials include the AIMS, the HAQ, the Quality (or Index) of Well Being, the MHIQ, and the MACTAR."},"gsx$tags":{"$t":"function"},"gsx$kind":{"$t":"composite"},"gsx$variable":{"$t":""},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":"aims,haq,qwb,iwb,mhiq,mactar"},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/7779114"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d180g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"apr"},"content":{"type":"text","$t":"nameshort: acute-phase reactant, namefriendly: acute-phase reactant value, namelong: Laboratory test, an acute-phase reactant value, description: \"A Westergren erythrocyte sedimentation rate or a C-reactive protein level.\", tags: biomarker, kind: assay, assessor: laboratory, includedmeasures: esr,crp"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d180g"}],"gsx$name":{"$t":"apr"},"gsx$nameshort":{"$t":"acute-phase reactant"},"gsx$namefriendly":{"$t":"acute-phase reactant value"},"gsx$namelong":{"$t":"Laboratory test, an acute-phase reactant value"},"gsx$description":{"$t":"\"A Westergren erythrocyte sedimentation rate or a C-reactive protein level.\""},"gsx$tags":{"$t":"biomarker"},"gsx$kind":{"$t":"assay"},"gsx$variable":{"$t":""},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"laboratory"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":"esr,crp"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d2mkx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"esr"},"content":{"type":"text","$t":"nameshort: sed rate, namefriendly: erythrocyte sedimentation rate, namelong: Laboratory test, erythrocyte sedimentation rate, description: A general laboratory test for inflammation, from any cause—including rheumatoid arthritis, infection, and even cancer, tags: biomarker, kind: assay, assessor: laboratory"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d2mkx"}],"gsx$name":{"$t":"esr"},"gsx$nameshort":{"$t":"sed rate"},"gsx$namefriendly":{"$t":"erythrocyte sedimentation rate"},"gsx$namelong":{"$t":"Laboratory test, erythrocyte sedimentation rate"},"gsx$description":{"$t":"A general laboratory test for inflammation, from any cause—including rheumatoid arthritis, infection, and even cancer"},"gsx$tags":{"$t":"biomarker"},"gsx$kind":{"$t":"assay"},"gsx$variable":{"$t":""},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"laboratory"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cssly"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"acr_20"},"content":{"type":"text","$t":"nameshort: ACR 20, namefriendly: 20% improvement, namelong: 20% improvement in RA symptoms, description: At least a 20% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain., tags: improvement, kind: composite, variable: dichotomous, includedmeasures: acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr, source: http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cssly"}],"gsx$name":{"$t":"acr_20"},"gsx$nameshort":{"$t":"ACR 20"},"gsx$namefriendly":{"$t":"20% improvement"},"gsx$namelong":{"$t":"20% improvement in RA symptoms"},"gsx$description":{"$t":"At least a 20% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain."},"gsx$tags":{"$t":"improvement"},"gsx$kind":{"$t":"composite"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":"acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr"},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cu76f"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"acr_50"},"content":{"type":"text","$t":"nameshort: ACR 50, namefriendly: 50% improvement, namelong: 50% improvement in RA symptoms, description: At least a 50% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain., tags: improvement, kind: composite, variable: dichotomous, includedmeasures: acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr, source: http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cu76f"}],"gsx$name":{"$t":"acr_50"},"gsx$nameshort":{"$t":"ACR 50"},"gsx$namefriendly":{"$t":"50% improvement"},"gsx$namelong":{"$t":"50% improvement in RA symptoms"},"gsx$description":{"$t":"At least a 50% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain."},"gsx$tags":{"$t":"improvement"},"gsx$kind":{"$t":"composite"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":"acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr"},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cvlqs"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"acr_70"},"content":{"type":"text","$t":"nameshort: ACR 70, namefriendly: 70% improvement, namelong: 70% improvement in RA symptoms, description: At least a 70% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain., tags: improvement, kind: composite, variable: dichotomous, includedmeasures: acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr, source: http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cvlqs"}],"gsx$name":{"$t":"acr_70"},"gsx$nameshort":{"$t":"ACR 70"},"gsx$namefriendly":{"$t":"70% improvement"},"gsx$namelong":{"$t":"70% improvement in RA symptoms"},"gsx$description":{"$t":"At least a 70% improvement in tender and swollen joint counts, and in at least three of five measures of disease activity or pain."},"gsx$tags":{"$t":"improvement"},"gsx$kind":{"$t":"composite"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":"acr_tjc,acr_sjc,patient_pain,patient_global_das,physician_global_das,patient_physical_function,apr"},"gsx$source":{"$t":"http://www.ncbi.nlm.nih.gov/pubmed/16273794"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cx0b9"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"discontinued_ae"},"content":{"type":"text","$t":"nameshort: withdrawal, namefriendly: discontinued due to an adverse event, namelong: withdrawal from a trial due to an adverse event or side effect, description: A participant left a study because of a side effect or \"adverse\" event, tags: adverse event,well being, kind: event, variable: dichotomous, assessor: clinician"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/cx0b9"}],"gsx$name":{"$t":"discontinued_ae"},"gsx$nameshort":{"$t":"withdrawal"},"gsx$namefriendly":{"$t":"discontinued due to an adverse event"},"gsx$namelong":{"$t":"withdrawal from a trial due to an adverse event or side effect"},"gsx$description":{"$t":"A participant left a study because of a side effect or \"adverse\" event"},"gsx$tags":{"$t":"adverse event,well being"},"gsx$kind":{"$t":"event"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d9ney"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"discontinued_efficacy"},"content":{"type":"text","$t":"nameshort: withdrawal, namefriendly: discontinued due to lack of efficacy, namelong: withdrawal from a trial due to lack of treatment efficacy, description: A participant left a study because they felt the medication wasn't working well, tags: satisfaction, kind: event, variable: dichotomous, assessor: clinician"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d9ney"}],"gsx$name":{"$t":"discontinued_efficacy"},"gsx$nameshort":{"$t":"withdrawal"},"gsx$namefriendly":{"$t":"discontinued due to lack of efficacy"},"gsx$namelong":{"$t":"withdrawal from a trial due to lack of treatment efficacy"},"gsx$description":{"$t":"A participant left a study because they felt the medication wasn't working well"},"gsx$tags":{"$t":"satisfaction"},"gsx$kind":{"$t":"event"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/db1zf"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"serious_ae"},"content":{"type":"text","$t":"nameshort: adverse event, namefriendly: serious adverse event, tags: adverse event, kind: event, variable: dichotomous, assessor: clinician"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/db1zf"}],"gsx$name":{"$t":"serious_ae"},"gsx$nameshort":{"$t":"adverse event"},"gsx$namefriendly":{"$t":"serious adverse event"},"gsx$namelong":{"$t":""},"gsx$description":{"$t":""},"gsx$tags":{"$t":"adverse event"},"gsx$kind":{"$t":"event"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"clinician"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/dcgjs"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"haq"},"content":{"type":"text","$t":"nameshort: HAQ, namefriendly: Health Assessment Questionnaire, namelong: score on the Health Assessment Questionnaire, tags: well being, kind: questionnaire, assessor: patient"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/dcgjs"}],"gsx$name":{"$t":"haq"},"gsx$nameshort":{"$t":"HAQ"},"gsx$namefriendly":{"$t":"Health Assessment Questionnaire"},"gsx$namelong":{"$t":"score on the Health Assessment Questionnaire"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"well being"},"gsx$kind":{"$t":"questionnaire"},"gsx$variable":{"$t":""},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ddv49"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"sf36_physical_20"},"content":{"type":"text","$t":"nameshort: SF-36, namefriendly: SF-36 physical 20% improvement, namelong: 20% improvement on the SF-36 health questionnaire physical component, tags: function,improvement, kind: questionnaire, variable: dichotomous, assessor: patient"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/ddv49"}],"gsx$name":{"$t":"sf36_physical_20"},"gsx$nameshort":{"$t":"SF-36"},"gsx$namefriendly":{"$t":"SF-36 physical 20% improvement"},"gsx$namelong":{"$t":"20% improvement on the SF-36 health questionnaire physical component"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"function,improvement"},"gsx$kind":{"$t":"questionnaire"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d415a"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"sf36_mental_20"},"content":{"type":"text","$t":"nameshort: SF-36, namefriendly: SF-36 mental 20% improvement, namelong: 20% improvement on the SF-36 health questionnaire mental component, tags: well being,improvement, kind: questionnaire, variable: dichotomous, assessor: patient"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d415a"}],"gsx$name":{"$t":"sf36_mental_20"},"gsx$nameshort":{"$t":"SF-36"},"gsx$namefriendly":{"$t":"SF-36 mental 20% improvement"},"gsx$namelong":{"$t":"20% improvement on the SF-36 health questionnaire mental component"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"well being,improvement"},"gsx$kind":{"$t":"questionnaire"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":"patient"},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d5fpr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"remission"},"content":{"type":"text","$t":"nameshort: remission, namefriendly: remission, namelong: disease remission, tags: remission,improvement, kind: event, variable: dichotomous"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d5fpr"}],"gsx$name":{"$t":"remission"},"gsx$nameshort":{"$t":"remission"},"gsx$namefriendly":{"$t":"remission"},"gsx$namelong":{"$t":"disease remission"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"remission,improvement"},"gsx$kind":{"$t":"event"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d6ua4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"permanent_work_disability"},"content":{"type":"text","$t":"nameshort: permanent work disability, namefriendly: permanent work disability, namelong: RA-related permanent work disability, tags: work,function, kind: event, variable: dichotomous"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d6ua4"}],"gsx$name":{"$t":"permanent_work_disability"},"gsx$nameshort":{"$t":"permanent work disability"},"gsx$namefriendly":{"$t":"permanent work disability"},"gsx$namelong":{"$t":"RA-related permanent work disability"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"work,function"},"gsx$kind":{"$t":"event"},"gsx$variable":{"$t":"dichotomous"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d88ul"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"median_work_disability_days"},"content":{"type":"text","$t":"nameshort: days off work, namefriendly: days off work due to RA, namelong: days off work due to RA (median), tags: work,function, kind: count, variable: interval"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o5079mk/public/values/d88ul"}],"gsx$name":{"$t":"median_work_disability_days"},"gsx$nameshort":{"$t":"days off work"},"gsx$namefriendly":{"$t":"days off work due to RA"},"gsx$namelong":{"$t":"days off work due to RA (median)"},"gsx$description":{"$t":""},"gsx$tags":{"$t":"work,function"},"gsx$kind":{"$t":"count"},"gsx$variable":{"$t":"interval"},"gsx$max":{"$t":""},"gsx$assessor":{"$t":""},"gsx$relatedmeasures":{"$t":""},"gsx$includedmeasures":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}}]}},
  mockMetrics   : {"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$gsx":"http://schemas.google.com/spreadsheets/2006/extended","id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"Metrics"},"link":[{"rel":"alternate","type":"application/atom+xml","href":"https://docs.google.com/spreadsheets/d/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/pubhtml"},{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values"},{"rel":"http://schemas.google.com/g/2005#post","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values"},{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values?alt=json"}],"author":[{"name":{"$t":"adamibaker"},"email":{"$t":"adamibaker@gmail.com"}}],"openSearch$totalResults":{"$t":"13"},"openSearch$startIndex":{"$t":"1"},"entry":[{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cokwr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"metric"},"content":{"type":"text","$t":"namefriendly: measure name (human-readable), notes: notes"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cokwr"}],"gsx$name":{"$t":"metric"},"gsx$nameshort":{"$t":""},"gsx$namefriendly":{"$t":"measure name (human-readable)"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":""},"gsx$source":{"$t":""},"gsx$notes":{"$t":"notes"}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cpzh4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"ar_100"},"content":{"type":"text","$t":"nameshort: absolute risk, namefriendly: absolute risk (out of 100), presentation: frequency"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cpzh4"}],"gsx$name":{"$t":"ar_100"},"gsx$nameshort":{"$t":"absolute risk"},"gsx$namefriendly":{"$t":"absolute risk (out of 100)"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"frequency"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cre1l"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"ar_1000"},"content":{"type":"text","$t":"nameshort: absolute risk, namefriendly: absolute risk (out of 1000), presentation: frequency"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cre1l"}],"gsx$name":{"$t":"ar_1000"},"gsx$nameshort":{"$t":"absolute risk"},"gsx$namefriendly":{"$t":"absolute risk (out of 1000)"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"frequency"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/chk2m"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"rr"},"content":{"type":"text","$t":"nameshort: relative risk, presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/chk2m"}],"gsx$name":{"$t":"rr"},"gsx$nameshort":{"$t":"relative risk"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/ciyn3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"or"},"content":{"type":"text","$t":"nameshort: odds ratio, presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/ciyn3"}],"gsx$name":{"$t":"or"},"gsx$nameshort":{"$t":"odds ratio"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/ckd7g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"abs_difference"},"content":{"type":"text","$t":"nameshort: absolute difference, namefriendly: absolute treatment benefit, presentation: percentage"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/ckd7g"}],"gsx$name":{"$t":"abs_difference"},"gsx$nameshort":{"$t":"absolute difference"},"gsx$namefriendly":{"$t":"absolute treatment benefit"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"percentage"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/clrrx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"rel_difference"},"content":{"type":"text","$t":"nameshort: relative difference, namefriendly: relative percent change, presentation: percentage"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/clrrx"}],"gsx$name":{"$t":"rel_difference"},"gsx$nameshort":{"$t":"relative difference"},"gsx$namefriendly":{"$t":"relative percent change"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"percentage"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cyevm"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"mean_score"},"content":{"type":"text","$t":"nameshort: mean score, presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cyevm"}],"gsx$name":{"$t":"mean_score"},"gsx$nameshort":{"$t":"mean score"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cztg3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"mean_score_difference"},"content":{"type":"text","$t":"nameshort: mean difference in score, description: \"The mean difference is the average difference between the intervention group and the control group across studies.\", presentation: value, source: http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cztg3"}],"gsx$name":{"$t":"mean_score_difference"},"gsx$nameshort":{"$t":"mean difference in score"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":"\"The mean difference is the average difference between the intervention group and the control group across studies.\""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":"http://www.cochranelibrary.com/about/explanations-for-cochrane-summary-of-findings-sof-tables.html"},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/d180g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"percentage"},"content":{"type":"text","$t":"nameshort: percentage, namefriendly: percentage of people, presentation: percentage"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/d180g"}],"gsx$name":{"$t":"percentage"},"gsx$nameshort":{"$t":"percentage"},"gsx$namefriendly":{"$t":"percentage of people"},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"percentage"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/d2mkx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"mean_score_10"},"content":{"type":"text","$t":"nameshort: mean score (out of 10), presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/d2mkx"}],"gsx$name":{"$t":"mean_score_10"},"gsx$nameshort":{"$t":"mean score (out of 10)"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cssly"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"mean_score_100"},"content":{"type":"text","$t":"nameshort: mean score (out of 100), presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cssly"}],"gsx$name":{"$t":"mean_score_100"},"gsx$nameshort":{"$t":"mean score (out of 100)"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cu76f"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"count"},"content":{"type":"text","$t":"nameshort: count, presentation: value"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/ojmf289/public/values/cu76f"}],"gsx$name":{"$t":"count"},"gsx$nameshort":{"$t":"count"},"gsx$namefriendly":{"$t":""},"gsx$description":{"$t":""},"gsx$presentation":{"$t":"value"},"gsx$source":{"$t":""},"gsx$notes":{"$t":""}}]}},
  mockTags      : {"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$gsx":"http://schemas.google.com/spreadsheets/2006/extended","id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"Tags"},"link":[{"rel":"alternate","type":"application/atom+xml","href":"https://docs.google.com/spreadsheets/d/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/pubhtml"},{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values"},{"rel":"http://schemas.google.com/g/2005#post","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values"},{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values?alt=json"}],"author":[{"name":{"$t":"adamibaker"},"email":{"$t":"adamibaker@gmail.com"}}],"openSearch$totalResults":{"$t":"9"},"openSearch$startIndex":{"$t":"1"},"entry":[{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cokwr"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"measure name / code"},"content":{"type":"text","$t":"namefriendly: measure name (human-readable)"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cokwr"}],"gsx$name":{"$t":"measure name / code"},"gsx$nameshort":{"$t":""},"gsx$namefriendly":{"$t":"measure name (human-readable)"},"gsx$description":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cpzh4"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"pain"},"content":{"type":"text","$t":"nameshort: Pain, namefriendly: Pain, description: Pain, including tenderness in joints and self-reported pain."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cpzh4"}],"gsx$name":{"$t":"pain"},"gsx$nameshort":{"$t":"Pain"},"gsx$namefriendly":{"$t":"Pain"},"gsx$description":{"$t":"Pain, including tenderness in joints and self-reported pain."}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cre1l"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"function"},"content":{"type":"text","$t":"nameshort: Physical function, namefriendly: Physical function, description: Ability to do daily activities, a combination of how you feel and how well your joints are working."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cre1l"}],"gsx$name":{"$t":"function"},"gsx$nameshort":{"$t":"Physical function"},"gsx$namefriendly":{"$t":"Physical function"},"gsx$description":{"$t":"Ability to do daily activities, a combination of how you feel and how well your joints are working."}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/chk2m"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"improvement"},"content":{"type":"text","$t":"nameshort: Overall improvement, namefriendly: Overall improvement, description: Overall improvement, usually measured by looking at a combination of swelling, pain, RA disease activity, and how you're feeling."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/chk2m"}],"gsx$name":{"$t":"improvement"},"gsx$nameshort":{"$t":"Overall improvement"},"gsx$namefriendly":{"$t":"Overall improvement"},"gsx$description":{"$t":"Overall improvement, usually measured by looking at a combination of swelling, pain, RA disease activity, and how you're feeling."}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/ciyn3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"satisfaction"},"content":{"type":"text","$t":"nameshort: Satisfaction, namefriendly: Satisfaction, description: Satisfaction with how well a treatment is working."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/ciyn3"}],"gsx$name":{"$t":"satisfaction"},"gsx$nameshort":{"$t":"Satisfaction"},"gsx$namefriendly":{"$t":"Satisfaction"},"gsx$description":{"$t":"Satisfaction with how well a treatment is working."}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/ckd7g"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"swelling"},"content":{"type":"text","$t":"nameshort: Swelling, namefriendly: Swollen joints"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/ckd7g"}],"gsx$name":{"$t":"swelling"},"gsx$nameshort":{"$t":"Swelling"},"gsx$namefriendly":{"$t":"Swollen joints"},"gsx$description":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/clrrx"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"biomarker"},"content":{"type":"text","$t":"nameshort: Lab results, namefriendly: Lab results"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/clrrx"}],"gsx$name":{"$t":"biomarker"},"gsx$nameshort":{"$t":"Lab results"},"gsx$namefriendly":{"$t":"Lab results"},"gsx$description":{"$t":""}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cyevm"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"adverse event"},"content":{"type":"text","$t":"nameshort: Side effects, namefriendly: Side effects, description: Side effects, adverse events (undesirable outcomes), etc."},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cyevm"}],"gsx$name":{"$t":"adverse event"},"gsx$nameshort":{"$t":"Side effects"},"gsx$namefriendly":{"$t":"Side effects"},"gsx$description":{"$t":"Side effects, adverse events (undesirable outcomes), etc."}},{"id":{"$t":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cztg3"},"updated":{"$t":"2015-03-28T18:50:20.622Z"},"category":[{"scheme":"http://schemas.google.com/spreadsheets/2006","term":"http://schemas.google.com/spreadsheets/2006#list"}],"title":{"type":"text","$t":"well being"},"content":{"type":"text","$t":"nameshort: Well being, namefriendly: Well being, description: ?"},"link":[{"rel":"self","type":"application/atom+xml","href":"https://spreadsheets.google.com/feeds/list/1AR88Qq6YzOFdVPgl9nWspLJrZXEBMBINHSjGADJ6ph0/o2pd8py/public/values/cztg3"}],"gsx$name":{"$t":"well being"},"gsx$nameshort":{"$t":"Well being"},"gsx$namefriendly":{"$t":"Well being"},"gsx$description":{"$t":"?"}}]}}
}

module.exports = mockData;